JPMorgan Chase & Co. cut its stake in Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,182,741 shares of the company’s stock after selling 17,778 shares during the quarter. JPMorgan Chase & Co. owned about 2.12% of Syneos Health worth $80,063,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of SYNH. Cresset Asset Management LLC boosted its stake in shares of Syneos Health by 12.0% in the first quarter. Cresset Asset Management LLC now owns 2,652 shares of the company’s stock valued at $214,000 after buying an additional 285 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Syneos Health by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 27,600 shares of the company’s stock worth $1,012,000 after acquiring an additional 300 shares in the last quarter. State of Michigan Retirement System boosted its position in Syneos Health by 1.2% during the fourth quarter. State of Michigan Retirement System now owns 26,222 shares of the company’s stock valued at $962,000 after purchasing an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Syneos Health by 2.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,683 shares of the company’s stock valued at $834,000 after acquiring an additional 361 shares during the period. Finally, Amalgamated Bank grew its position in Syneos Health by 0.5% during the 3rd quarter. Amalgamated Bank now owns 74,321 shares of the company’s stock worth $3,504,000 after acquiring an additional 367 shares during the last quarter. 93.51% of the stock is currently owned by hedge funds and other institutional investors.
Syneos Health Trading Down 0.1 %
Shares of SYNH stock opened at $41.53 on Wednesday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.15. The firm has a market capitalization of $4.30 billion, a PE ratio of 29.04 and a beta of 1.61. The stock has a fifty day moving average of $39.57 and a two-hundred day moving average of $37.17. Syneos Health, Inc. has a 1 year low of $22.89 and a 1 year high of $79.77.
Analyst Upgrades and Downgrades
SYNH has been the subject of several analyst reports. Robert W. Baird cut Syneos Health from an “outperform” rating to a “neutral” rating in a report on Thursday, May 11th. Mizuho increased their target price on shares of Syneos Health from $38.00 to $43.00 in a research report on Tuesday, May 16th. Deutsche Bank Aktiengesellschaft lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. JPMorgan Chase & Co. raised shares of Syneos Health from an “underweight” rating to a “neutral” rating in a research report on Wednesday, May 10th. Finally, Barclays raised shares of Syneos Health from an “underweight” rating to an “equal weight” rating in a report on Wednesday, May 10th. Ten equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $47.63.
Syneos Health Profile
Syneos Health, Inc, operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
See Also
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health, Inc. (NASDAQ:SYNH – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Syneos Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Syneos Health wasn’t on the list.
While Syneos Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
